Other external R&D expenses — R&D
Insmed Other external R&D expenses — R&D decreased by 11.1% to $32.68M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.4%, from $28.08M to $32.68M. Over 3 years (FY 2022 to FY 2025), Other external R&D expenses — R&D shows an upward trend with a 56.0% CAGR.
Analysis
How to read this metric
An increase may indicate expanded investment in early-stage discovery or platform technology, while a decrease could suggest a focus on cost-cutting or a shift toward prioritizing specific late-stage clinical assets.
Detailed definition
This metric represents the costs incurred for outsourced research and development activities that are not directly attri...
Peer comparison
Peers in the biopharmaceutical industry often report this as 'Other R&D' or 'Unallocated R&D' expenses, which typically fluctuate based on the maturity of the pipeline and the intensity of early-stage discovery efforts.
insm_segment_other_external_r_d_expenses_research_and_developmentHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.55M | $8.55M | $8.55M | $8.55M | $33.16M | $33.16M | $33.16M | $33.16M | $13.28M | $14.92M | $26.92M | $35.49M | $28.08M | $28.45M | $36.58M | $36.76M | $32.68M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +287.9% | +0.0% | +0.0% | +0.0% | -60.0% | +12.4% | +80.5% | +31.9% | -20.9% | +1.3% | +28.6% | +0.5% | -11.1% |
| YoY Change | — | — | — | — | +287.9% | +287.9% | +287.9% | +287.9% | -60.0% | -55.0% | -18.8% | +7.0% | +111.5% | +90.7% | +35.9% | +3.6% | +16.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's other external r&d expenses — r&d?
- Insmed (INSM) reported other external r&d expenses — r&d of $32.68M in Q1 2026.
- How has Insmed's other external r&d expenses — r&d changed year-over-year?
- Insmed's other external r&d expenses — r&d increased by 16.4% year-over-year, from $28.08M to $32.68M.
- What is the long-term trend for Insmed's other external r&d expenses — r&d?
- Over 3 years (2022 to 2025), Insmed's other external r&d expenses — r&d has grown at a 56.0% compound annual growth rate (CAGR), from $34.20M to $129.87M.
- What does other external r&d expenses — r&d mean?
- The total amount spent on outsourced research and development activities not tied to a specific primary clinical trial.